YZYunyue Zhang

Yunyue Zhang

*This is an algorithmically generated author record based on publicly available information.

Yunyue Zhang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Eric J. Topol

    Scripps Research Translational Institute, Scripps Research, La Jolla, USA

    2 shared publications
  • Austin Zhang

    Grandview High School

    1 shared publication
  • Dov Shiffman

    Quest Diagnostics, San Juan Capistrano, California, United States of America

    1 shared publication
  • Emily G. Spencer

    Scripps Research Translational Institute, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, United States, 1 858-784-1000

    1 shared publication
  • Eric J. Topol

    Scripps Translational Science Institute, The Scripps Research Institute, La Jolla, California; Division of Cardiovascular Disease, Scripps Clinic, Scripps Health, La Jolla, California; Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California

    1 shared publication
  • Evan D. Muse

    Scripps Translational Science Institute, The Scripps Research Institute, La Jolla, California; Division of Cardiovascular Disease, Scripps Clinic, Scripps Health, La Jolla, California

    1 shared publication

Latest Publications

  • Open Access

    The Impact of X (Formerly Twitter) Sentiment on Stock Returns Using Machine Learning Models

    by Austin Zhang, Yunyue Zhang

    The financial world is influenced by numerous factors such as social media. Posts on platforms like X (formerly Twitter) may reflect investors’ sentiment and therefore impact the growth of the stock market. In January 2021, Reddit users heavily impacted the Gamestop stock as well as the overall stock market with only a few posts (New York Times, 2021). There exist many similar instances where online statements from individuals or groups changed the direction of a stock (CNBC, 2023). In this study, we analyzed social media data to determine whether different artificial intelligence models can predict the direction of future stock movements. We used Random Forest, K Nearest Neighbors, and Ridge models to analyze 367,666 tweets from X and predict the stocks’ direction of change over the course of 1 day or up to 1 week. The performance of these models was assessed by a common metric, F1 score, ranging from 0 to 1 where 0 indicates poor performance and 1 indicates perfect performance. The evaluated machine learning models predicted the direction with F1 Scores of around 0.8, peaking at 0.9, indicating that tweets and social media posts can be used as a tool to guide financial investment. Further studies can investigate the longevity of the impact of specific tweets, incorporating more tweet-related features such as the counts of retweets, followers, and likes.

  • Open Access

    Trends in Prices of Popular Brand-Name Prescription Drugs in the United States

    by Nathan E. Wineinger, Yunyue Zhang, Eric J. Topol

    Pharmaceutical drug net spending in the United States reached $324 billion in 2017 and is expected to increase 2% to 5% annually over the next 5 years.1 Per capita pharmaceutical spending is 54% to 209% higher in the United States than other high-income countries2 because of higher prices and widening differential of pay between public and private insurers.3 This trend persists despite an increase in the proportion of generic drugs prescribed,4 which has lowered spending when generic drugs are available,5 and is associated with the high and growing costs of brand-name drugs granted government-protected market exclusivity.6 (Throughout the text, we refer to cost as the price paid for purchasing a drug and not as manufacturing cost.)


  • Identification of paroxysmal atrial fibrillation subtypes in over 13,000 individuals

    by Nathan E. Wineinger, Paddy M. Barrett, Yunyue Zhang, Ikram Irfanullah, Evan D. Muse, Steven R. Steinhubl, Eric J. Topol


  • Open Access

    Validation of a genetic risk score for atrial fibrillation: A prospective multicenter cohort study

    by Evan D Muse, Nathan E Wineinger, Emily G Spencer, Melissa Peters, Riley Henderson, Yunyue Zhang, Paddy M Barrett, Steven P Rivera, Jay G Wohlgemuth, James J Devlin, et al.

    Atrial fibrillation (AF) is the most commonly encountered arrhythmia and is associated with an elevated risk of stroke. Improving the identification of patients with the highest risk for AF to enable appropriate surveillance and treatment, if necessary, is critical to reducing AF-associated morbidity and mortality. Multiple common single nucleotide polymorphisms (SNPs) are unequivocally associated with the lifetime risk of AF. In the current study we aimed to prospectively validate an AF genetic risk score (GRS) in previously undiagnosed patients at risk for AF. Individuals 40 years of age or older with 1 clinical risk factor for AF, presenting with symptoms of AF, or with a first diagnosis of AF, were enrolled for genetic testing and ambulatory cardiac rhythm monitoring with an adhesive patch monitor or a long-term Holter monitor (mean wear time 10 days 21 hours and 13 days 18 hours, respectively). An AF event was the first diagnosis of AF by ECG, patch monitor, or long-term Holter monitor. The AF GRS was determined for each participant based on the weighted contribution of 12 genetic risk loci. Of 904 participants, 85 manifested AF. Their mean age was 66.2 (SD 11.8) years; 38% of participants were male. Participants in the highest quintile of AF GRS were more likely (odds ratio 3.11; 95% CI 1.27–7.58; p = 0.01) to have had an AF event than participants in the lowest quintile after adjusting for age, sex, smoking status, BMI, hypertension, diabetes mellitus, heart failure, and prior myocardial infarction. Study limitations included an ethnically homogenous population, a restricted rhythm monitoring period, and the evolving discovery of SNPs associated with AF. Prospective assessment of a GRS for AF identified participants with elevated risk of AF beyond established clinical criteria. Accordingly, a GRS for AF could be incorporated into overall risk assessment to better identify patients at the highest risk of developing AF, although further testing in larger populations is needed to confirm these findings. ClinicalTrials.gov NCT01970969